Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1977 Feb;74(2):769–773. doi: 10.1073/pnas.74.2.769

Opposing effects of dopaminergic to cholinergic compounds on a cerebral dopamine-activated adenylate cyclase.

L C Tang, G C Cotzias
PMCID: PMC392375  PMID: 265541

Abstract

In contrast to antipsychosis drugs which inhibit the dopamine-activated adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] of caudate nucleus, dopaminergic drugs for treatment of Parkinson's disease stimulate this cyclase. Stimulants and inhibitors of cholinergic neurons inhibited this adenylate cyclase activity competitively and specifically. Thus, the mechanism by which dopaminergic medications ameliorate the effects of Parkinson's disease includes activation of the dopamine-sensitive adenylate cyclase. Excessive activation might be present during the psychotic episodes seen in patients with parkinsonism who are overtreated. The enzymatic effects of the drugs that affect cholinergic mechanisms seem to be generally in keeping with the pharmacological reciprocity between psychoses and extrapyramidal function, except for the anticholinergic ones which inhibited this cyclase although they can be hallucinogenic.

Full text

PDF
769

Images in this article

771Image
on p.771

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clement-Cormier Y. C., Kebabian J. W., Petzold G. L., Greengard P. Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs. Proc Natl Acad Sci U S A. 1974 Apr;71(4):1113–1117. doi: 10.1073/pnas.71.4.1113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clement-Cormier Y. C., Parrish R. G., Petzold G. L., Kerabian J. W., Greengard P. Characterization of a dopamine-sensitive adenylate cyclase in the rat caudate nucleus. J Neurochem. 1975 Aug;25(2):143–149. doi: 10.1111/j.1471-4159.1975.tb12241.x. [DOI] [PubMed] [Google Scholar]
  3. Costall B., Naylor R. J. Dopamine agonist and antagonist activities of piribedil (ET495)and its metabolites. Naunyn Schmiedebergs Arch Pharmacol. 1974;285(1):71–81. doi: 10.1007/BF00499528. [DOI] [PubMed] [Google Scholar]
  4. Cotzias G. C. Levodopa, manganese, and degenerations of the brain. Harvey Lect. 1974;68:115–147. [PubMed] [Google Scholar]
  5. Cotzias G. C., Papavasiliou P. S., Ginos J., Steck A., Düby S. Metabolic modification of Parkinson's disease and of chronic manganese poisoning. Annu Rev Med. 1971;22:305–326. doi: 10.1146/annurev.me.22.020171.001513. [DOI] [PubMed] [Google Scholar]
  6. Cotzias G. C., Papavasiliou P. S., Tolosa E. S., Mendez J. S., Bell-Midura M. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. N Engl J Med. 1976 Mar 11;294(11):567–572. doi: 10.1056/NEJM197603112941101. [DOI] [PubMed] [Google Scholar]
  7. Duvoisin R. C. Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol. 1967 Aug;17(2):124–136. doi: 10.1001/archneur.1967.00470260014002. [DOI] [PubMed] [Google Scholar]
  8. Düby S. E., Cotzias G. C., Papavasiliou P. S., Lawrence W. H. Injected apomorphine and orally administered levodopa in Parkinsonism. Arch Neurol. 1972 Dec;27(6):474–480. doi: 10.1001/archneur.1972.00490180010004. [DOI] [PubMed] [Google Scholar]
  9. Gilman A. G. A protein binding assay for adenosine 3':5'-cyclic monophosphate. Proc Natl Acad Sci U S A. 1970 Sep;67(1):305–312. doi: 10.1073/pnas.67.1.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ginos J. Z., Cotzias G. C., Tolosa E., Tang L. C., LoMonte A. Cholinergic effects of molecular segments of apomorphine and dopaminergic effects of N,N-dialkylated dopamines. J Med Chem. 1975 Dec;18(12):1194–1200. doi: 10.1021/jm00246a005. [DOI] [PubMed] [Google Scholar]
  11. Karobath M., Leitich H. Antipsychotic drugs and dopamine-stimulated adenylate cyclase prepared from corpus striatum of rat brain. Proc Natl Acad Sci U S A. 1974 Jul;71(7):2915–2918. doi: 10.1073/pnas.71.7.2915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kebabian J. W., Petzold G. L., Greengard P. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor". Proc Natl Acad Sci U S A. 1972 Aug;69(8):2145–2149. doi: 10.1073/pnas.69.8.2145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Klawans H. L., Jr The pharmacology of parkinsonism (a review). Dis Nerv Syst. 1968 Dec;29(12):805–816. [PubMed] [Google Scholar]
  14. Koelle G. B. Acetylcholine--current status in physiology, pharmacology and medicine. N Engl J Med. 1972 May 18;286(20):1086–1090. doi: 10.1056/NEJM197205182862006. [DOI] [PubMed] [Google Scholar]
  15. Miller R. J., Hiley C. R. Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature. 1974 Apr 12;248(449):596–597. doi: 10.1038/248596a0. [DOI] [PubMed] [Google Scholar]
  16. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975 Jun 20;188(4194):1217–1219. doi: 10.1126/science.1145194. [DOI] [PubMed] [Google Scholar]
  17. Snyder S. H., Banerjee S. P., Yamamura H. I., Greenberg D. Drugs, neurotransmitters, and schizophrenia. Science. 1974 Jun 21;184(4143):1243–1253. doi: 10.1126/science.184.4143.1243. [DOI] [PubMed] [Google Scholar]
  18. Snyder S., Greenberg D., Yamamura H. I. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 1974 Jul;31(1):58–61. doi: 10.1001/archpsyc.1974.01760130040006. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES